Could a diabetes drug help obese patients get better knee replacements?
NCT ID NCT06807970
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests whether the weight-loss drug semaglutide can improve outcomes for obese patients waiting for total knee replacement. 54 participants will receive the drug for 48 weeks before and after surgery. The goal is to see if weight loss reduces pain and complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide (a glucagon-like peptide-1 receptor agonist, GLP-1 RA)
- What this could lead to
- If it works, this could show that weight loss with semaglutide before knee replacement reduces pain and complications in obese patients.
- What could go wrong
- This is a very early, small trial (54 people) with no results yet. The drug may not improve outcomes and can cause side effects like nausea or pancreatitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) OF THE KNEE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear cartilage to the rescue? a tiny biopsy could rebuild knees
- Which knee surgery approach gets you back on your feet faster?
- Can a lotion outperform standard gel for knee pain?
- A digital coach for knee replacement recovery — can it boost satisfaction and exercise?
- Virtual program aims to keep joint replacement patients moving while they wait
- Cheaper collagen injection could rival standard knee OA treatment